Legal status by country
Is BGM0504 legal?
Written by Aaron CuhaReviewed Sep 2026
How BGM0504 is classified in the United States, United Kingdom, Australia and Canada, side by side. Each country has its own page with a direct answer, the regulator's approval status and what the classification means in practice.
All four countries, side by side
| Attribute | United States · FDA | United Kingdom · MHRA | Australia · TGA | Canada · Health Canada |
|---|---|---|---|---|
| Status | Not approved | Not approved | Not approved | Not approved |
| Classification | Investigational, not approved | Investigational, not licensed | Investigational, not registered | Investigational, not approved |
| Note | No approval and no registered United States trial located. The clinical programme is in China and Indonesia. | No MHRA filing located. | None recorded | None recorded |
US FDA status: Not approved anywhere. Multiple phase 3 trials are recruiting in China and Indonesia, and a tablet formulation is in phase 1. The phase 3 obesity result announced in May 2026 has not been published in a peer-reviewed journal as of this review.. Reviewed Sep 2026.
Related compounds
General information current as of Sep 2026, not legal advice. Classifications change; confirm with the regulator or a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships.